Education
About Us
Working with TipRanks
Follow Us
Zai Lab Ltd (ZLAB)
:ZLAB
ZLAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.48 - $39.61
Previous CloseN/A
Volume273.50K
Average Volume (3M)1.09M
Market Cap
$4.21B
Enterprise Value$1.78B
Total Cash (Recent Filing)$449.67M
Total Debt (Recent Filing)$153.47M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 13, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding109,628,370
10 Day Avg. Volume817,571
30 Day Avg. Volume1,085,928
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.39
Price to Cash Flow (P/CF)-18.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.09
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$54.03Price Target Upside40.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceZai Lab registered a significant increase in total revenue by 49.6%, aligning with the forecast and driven by the ramp-up of VYVGART.
Future Growth PotentialThe projected revenue guidance for 2025 indicates a significant increase, suggesting strong future growth potential.
Product DevelopmentZLAB highlighted the launch of two key regional programs in 2025-26 as potential blockbuster drugs, including bemarituzumab.
Bears Say
Analyst RatingZai Lab has been downgraded to a Neutral rating due to a growth slowdown of core products and near-term positive news seems to have been priced in.
Product PerformanceSome core products like Zejula and Optune have seen soft performance, impacting overall growth.
Stock ValuationRecent positive news and product approvals have already been factored into the stock price, limiting short-term upside potential.
---
Ownership Overview
1.31% Insiders
20.21% Mutual Funds
21.69% Other Institutional Investors
55.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZLAB FAQ
What was Zai Lab Ltd’s price range in the past 12 months?
Zai Lab Ltd lowest stock price was $13.48 and its highest was $39.61 in the past 12 months.
What is Zai Lab Ltd’s market cap?
Zai Lab Ltd’s market cap is $4.21B.
When is Zai Lab Ltd’s upcoming earnings report date?
Zai Lab Ltd’s upcoming earnings report date is May 13, 2025 which is in 55 days.
How were Zai Lab Ltd’s earnings last quarter?
Zai Lab Ltd released its earnings results on Feb 27, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.651 by -$0.149.
Is Zai Lab Ltd overvalued?
According to Wall Street analysts Zai Lab Ltd’s price is currently Undervalued.
Does Zai Lab Ltd pay dividends?
Zai Lab Ltd does not currently pay dividends.
What is Zai Lab Ltd’s EPS estimate?
Zai Lab Ltd’s EPS estimate is -0.46.
How many shares outstanding does Zai Lab Ltd have?
Zai Lab Ltd has 109,628,370 shares outstanding.
What happened to Zai Lab Ltd’s price movement after its last earnings report?
Zai Lab Ltd reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.651. Following the earnings report the stock price went down -1.967%.
Which hedge fund is a major shareholder of Zai Lab Ltd?
Currently, no hedge funds are holding shares in ZLAB
---
Zai Lab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.03 (40.89% Upside)
$54.03 (40.89% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 503.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.73%
12-Months-Change
Fundamentals
Return on Equity
-31.41%
Trailing 12-Months
Asset Growth
14.42%
Trailing 12-Months
Company Description
Zai Lab Ltd
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
---
ZLAB Company Deck
---
ZLAB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong revenue growth, successful product launches, and pipeline advancements. Despite some challenges, such as limited immediate impact from certain product launches and competitive pressures, the company is on track towards profitability and maintains a strong cash position.Read More>---
ZLAB Stock 12 Month Forecast
Average Price Target
$54.03
▲(40.89% Upside)
Technical Analysis
Best Analysts Covering ZLAB
1 Year
1 Year Success Rate
17/34 ratings generated profit
1 Year Average Return
+12.98%
reiterated a buy rating 20 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.98% per trade.
---